FundedIQ
Biotechnology

CinCor Pharma: Funding, Investors & Team (Aug 2026)

CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor’s focus is on cardiovascular, metabolic and kidney diseases. CinCor’s lead program is CIN-107, a novel aldosterone synthase inhibitor.

cincor.com LinkedIn Cincinnati, United States 11-50 employees
Biotechnology Pharmaceutical Therapeutics
Total raised
$225M
Rounds
1
Latest
Post-IPO Equity
Aug 2022

CinCor Pharma has raised $225M across 1 funding round on record, the most recent a Post-IPO Equity of $225M announced in Aug 2022.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

CinCor Pharma Company Profile and Key Stats

Total funding raised
$225M
across 1 round on record
Funding rounds on record
1
Latest funding round
Post-IPO Equity
$225M in Aug 2022
Employees
11-50
reported band
Headquarters
Cincinnati, United States

Latest funding round on record: Aug 2022.

CinCor Pharma Funding Rounds

Date
Round
Amount
Post-IPO Equity
$225M

CinCor Pharma Founders and Leadership Team

Name
Role
Contact
Marc De Garidel
CEO

No contact details are on record for this team yet.

CinCor Pharma Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round

CinCor Pharma's latest round of $225M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like CinCor Pharma in Biotechnology and Cincinnati

Companies Similar to CinCor Pharma

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…

Series A $6.3M

Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.

Series C $90.0M

Cataract surgery is the single most common procedure performed in the United States annually. Despite…

Series A $7.0M

InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…

Convertible Note $1.3M

Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…

Series A $10.0M

CinCor Pharma Funding FAQs

What does CinCor Pharma do?

CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor’s focus is on cardiovascular, metabolic and kidney diseases. CinCor’s lead program is CIN-107, a novel aldosterone synthase inhibitor.

How much funding has CinCor Pharma raised?

CinCor Pharma has raised $225M across 1 round on record. The most recent is a Post-IPO Equity of $225M announced in Aug 2022.

When did CinCor Pharma last raise funding?

CinCor Pharma's most recent funding round on record is a Post-IPO Equity of $225M, announced in Aug 2022.

Who is the CEO of CinCor Pharma?

Marc De Garidel is listed as CEO at CinCor Pharma.

Where is CinCor Pharma headquartered?

CinCor Pharma is based in Cincinnati, Ohio, United States.

How many employees does CinCor Pharma have?

CinCor Pharma is in the 11-50 employee band.

How does CinCor Pharma's funding compare to other Biotechnology startups?

CinCor Pharma's latest round of $225M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's CinCor Pharma Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CinCor Pharma is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.